Targeting Protein Disulfide Isomerase with the Oral Flavonoid Isoquercetin Prevents Venous Thromboembolism in Advanced Cancer: Results of a Multi-Dose, Multi-Center, Phase II Clinical Trial (CATIQ Study)

ConclusionsThe oral flavonoid, isoquercetin, prevented venous thromboembolism in cancer without an observed increase in hemorrhage. These results represent the first evidence in humans that targeting extracellular PDI has antithrombotic efficacy in a high VTE-risk population and implicate PDI-targeted therapies as a new class of antithrombotic therapeutics. (Clinicaltrials.gov #NCT02195232).FigureDisclosuresZwicker: Daiichi: Honoraria; Quercegen: Research Funding; Parexel: Consultancy; Incyte: Research Funding.

Source: Blood - November 21, 2018 Category: Hematology Authors: Zwicker, J. I., Schlechter, B. L., Stopa, J. D., Liebman, H. A., Aggarwal, A., Caughey, T., Bauer, K. A., Kuemmerle, N., Wong, E. Y., Wun, T., Mclaughlin, M., Puligandla, M., Neuberg, D. S., Furie, B., Flaumenhaft, R. C. Tags: 332. Antithrombotic Therapy: New Drugs and Technology Source Type: research